August 29, 2017

Ferring Pharmaceuticals to Donate $25,000 to Hurricane Harvey Relief

PARSIPPANY, N.J., August 29, 2017 – Ferring Pharmaceuticals announced today that it will donate $25,000 to help the people and communities impacted by Hurricane Harvey. Ferring will make its donation to the American Red Cross, which has mobilized its resources to respond to the devastation in Texas and across the Gulf Coast region.

“Our thoughts and prayers are with Texas and the Gulf Coast,” said Paul Navarre, CEO, Ferring Holding Inc. “We are providing support to the Hurricane Harvey relief efforts of the American Red Cross on behalf of all Ferring employees.”

###

 

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

 

For further information:

Patrick Gorman

862-286-5035

patrick.gorman@ferring.com

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, EUFLEXXA, FIRMAGON, and PREPOPIK are registered trademarks of Ferring B.V. ZOMACTON is a trademark of Ferring B.V.

©2008-2015 Ferring Pharmaceuticals.  GC/1722/2014/US(4)